Devices using Crosstrees Pod technology feature a polymer material constructed to control the delivery of PMMA (polymethylmethacrylate) bone cement to the fracture site.
based Crosstrees is developing and commercializing a product portfolio that addresses the demand for improved vertebral fracture treatment.
has developed a portfolio of issued patents in the United States, EU, China, and Taiwan, with additional applications pending for a broad portfolio of therapeutic devices and methods of use.
The Great Lie by Myrrha Stanford-Smith The docks were still for once, the incessant hammering silenced as he rode, weary and saddle-sore through Deptford to Crosstrees
, Fearghas cantering at his side.
Research and Development staff at Crosstrees developed the patented technology to address the need for improved vertebral fracture repair devices that can potentially reduce risk of complications in vertebral augmentation procedures, such as nerve root compression, pulmonary embolism, and arterial embolism, reported in the published literature.
The Crosstrees Pod(TM) System offers performance benefits that may significantly improve surgical outcomes for patients with vertebral fractures," said Robert Scribner, President & CEO of Crosstrees Medical, Inc.
Key regions - Americas - APAC - EMEA Key vendors - CareFusion - DePuy Synthes - Medtronic - Stryker Other prominent vendor - AOI Medical - Benvenue Medical - Biomet - Bone Support - Cook Medical - Crosstrees
Medical - DFine - Joimax - Joline - Maxxspine - SI-BONE - Tecres - Vexim - Zavation Market driver High prevalence of osteoporosis For a full, detailed list, view our report Market challenge High cost of VCF repair surgeries For a full, detailed list, view our report Market trend Focus on reducing risks of cement leakage For a full, detailed list, view our report
Pod(TM) System offers multiple opportunities for improved surgical outcomes for patients with degenerative spine conditions," said Robert Scribner, President & CEO of Crosstrees
Lieberman is a paid consultant to Kyphon, he is a paid consultant and owns stock or has stock options in Crosstrees
, Merlot OrthopediX, Trans1, Axiomed, Mazor Surgical, and he receives royalties from DePuy Spine and Stryker Spine.